Show simple item record

dc.contributor.authorWalsh, Lorraine
dc.contributor.authorGillham, Charles
dc.contributor.authorDunne, Mary
dc.contributor.authorFraser, Ian
dc.contributor.authorHollywood, Donal
dc.contributor.authorArmstrong, John
dc.contributor.authorThirion, Pierre
dc.date.accessioned2011-05-25T13:29:52Z
dc.date.available2011-05-25T13:29:52Z
dc.date.issued2011-01
dc.identifier.citationToxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). 2011, 98 (1):38-41 Radiother Oncolen
dc.identifier.issn1879-0887
dc.identifier.pmid21159400
dc.identifier.doi10.1016/j.radonc.2010.11.009
dc.identifier.urihttp://hdl.handle.net/10147/132015
dc.descriptionWe retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications.en
dc.description.abstractWe retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications.
dc.language.isoenen
dc.publisherElsevieren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarcinoma
dc.subject.meshCisplatin
dc.subject.meshCombined Modality Therapy
dc.subject.meshFemale
dc.subject.meshHead and Neck Neoplasms
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms, Squamous Cell
dc.subject.meshPatient Compliance
dc.subject.meshRadiotherapy Dosage
dc.subject.meshRetrospective Studies
dc.titleToxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland.en
dc.identifier.journalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncologyen
dc.description.provinceLeinster
html.description.abstractWe retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record